CA-JUNIPER-NETWORKS
12.12.2023 08:01:36 CET | Business Wire | Press release
Juniper Networks® (NYSE: JNPR), a leader in secure, AI-driven networks, and NEC Corporation (NEC; TSE: 6701), a leading global IT and network transformation services provider, today announced that DNA, part of Telenor Group and one of Finland’s leading mobile and fixed communications service providers, has deployed an intent-based networking data center fabric based on Juniper’s innovative automation software plus high-performance hardware and utilizing NEC’s advanced systems integration expertise. DNA’s new data center infrastructure provides a unified platform for both its business-to-business customer services and internal IT services. Additionally, Juniper Networks™ QFX Series Switches were chosen to power DNA’s Telco Cloud sites across Finland.
The overall objective for DNA’s data center infrastructure refresh is to enable new revenue-generating services whilst delivering operational efficiencies, together leading to enhanced user experiences. By automating the data center network, DNA can eliminate human error, optimize its technical team’s workload to focus on service creation and simplify first-class service delivery at scale. QFX switches enable low latency networking with high reliability and capacity, the key requirements for delivering various services to mobile users who are looking for high-performance network quality.
Juniper Apstra System: Intent-based Networking
- DNA has selected the Juniper Apstra solution as the data center infrastructure’s foundation: unique, intent-based networking software that simplifies, automates and validates data center design, planning and operations, from Day 0 to Day 2+.
- Apstra is a turnkey multi-vendor automation solution (both hardware- and OS-agnostic), that provides DNA with a unified, real-time view of millions of data center elements, plus their dynamic performance, relationships and interdependencies.
- Apstra’s capabilities bring agility and more reliability to DNA’s network design, build and operations. The entire network management operations will be streamlined, and IT teams will be able to focus more on other priorities.
- With Apstra, DNA can create a set of templates for its data center network built on its desired intent and required business outcomes. Apstra automatically converts this intent into the network configurations and policies necessary to consistently achieve DNA’s defined outcomes.
- The Apstra-enabled network undergoes continuous, closed-loop assurance and self-validation to ensure compliance with the declared intent from the blueprint.
- Using the operational, real-time analytics it constantly generates, Apstra is also able to deliver much faster and highly-accurate root-cause analysis of network issues and mitigation data, helping DNA to maximize its data center and services uptime.
- DNA also deployed Juniper Networks QFX Series Switches across its new data center fabric. The QFX Series complements Apstra in DNA’s network by delivering industry-leading reliability, performance and scalability.
- NEC is the strategic partner for DNA, providing pre-integration consultancy and validation as well as premium level support for Juniper’s solution, leveraging its expert support team of certified engineers.
Supporting Quotes:
“DNA has always been an innovator, using the best technology available to provide new services and better experiences for our customers. Because Finnish businesses are fully committed to digital transformation, and their expectations of our service reliability and quality are extremely high, we knew that we had to up our game in the data center by deploying state-of-the-art automation and networking technology. By working with Juniper and NEC, DNA is able to deliver those first-class user experiences and maintain our reputation.”
- Pekka Jääskeläinen, Vice President, Core & IP Networks, DNA Plc
“As a long-standing partner to the Telenor Group, NEC is honored to help DNA drive higher efficiency, agility, and availability of its data center network with automated solutions alongside our strategic partner Juniper. Based on our wealth of multi-vendor, multi-domain network systems integration capability and best-of-breed ecosystem, provided by NEC’s Center of Excellence (CoE), we will continue delivering transformative networking solutions and services that overcome increasing business challenges and keep our customers ahead of the curve.”
- Masayuki Kayahara, General Manager, Service Provider Solutions Department, NEC
“Apstra helps to de-risk data center networking significantly but also streamlines the operational overhead, making life much easier for pressured operators. Automation drives down the total cost of ownership in DNA’s data centers and frees up talent, all the while enabling it to open up rich new revenue streams via services which can be taken to market quickly and more reliably.”
- Mansour Karam, Group Vice President Products, Cloud Ready Data Center, Juniper Networks
Additional Resources
Blog: DIY Network Automation – a High-cost Operation for Telecom Data Centers
Research Topic: What is Intent-based Networking?
Infographic: The State of Data Center Network Automation
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on X (formerly Twitter), LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at http://www.nec.com.
LinkedIn: https://www.linkedin.com/company/nec/
YouTube: https://www.youtube.com/user/NECglobalOfficial
Facebook: https://www.facebook.com/nec.global/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231206095386/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom